BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create...
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly...
BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element...
BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic...
Stay connected
Partner with BroadOak